-+ 0.00%
-+ 0.00%
-+ 0.00%

Astellas doses first patient in Phase 3 study of ASP2138 for CLDN18.2-positive gastric, GEJ cancer

PUBT·08/24/2026 23:30:25
Listen to the news
Astellas doses first patient in Phase 3 study of ASP2138 for CLDN18.2-positive gastric, GEJ cancer
  • Astellas dosed the first patient in a Phase 3 trial of ASP2138 for first-line CLDN18.2-positive, HER2-negative advanced gastric or GEJ cancer.
  • The study tests ASP2138 with chemotherapy, with pembrolizumab included in the regimen.
  • ASP2138 is an investigational subcutaneous bispecific antibody targeting CLDN18.2 on tumors, CD3 on T cells to drive tumor killing.
  • The program anchors Astellas’ immuno-oncology focus, supporting its goal to start at least five Phase 3 or pivotal studies by fiscal 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astellas Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608241930PR_NEWS_USPR_____CG31815) on August 24, 2026, and is solely responsible for the information contained therein.